我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

The Clinical Impact of Molecular Techniques to Differentiate Cancer Cells from Healthy Cells

Richard Steensma

The use of molecular methods in diagnostic histopathology has grown increasingly important [1]. They have been quite effective in treating sarcomas in both soft tissue and bone [2]. The employment of auxiliary molecular diagnostic methods is very beneficial because sarcomas are relatively uncommon and difficult to diagnose [3]. Due to the findings of earlier and continuing studies, it is also discovered that particular genetic variations are closely connected with a variety of different mesenchymal lesions. Better illness definition, which results in more accurate diagnostics, the discovery of molecular predictive and prognostic markers, the unravelling of novel molecular targets for more focused treatment approaches, and ultimately drug development are all made possible by molecular techniques [4]. When choosing the appropriate materials for these analyses, the pathologist plays a significant role [5]. Selecting the most appropriate technology for the problems at hand, and 3. Combining the findings of these analyses with the clinic pathological characteristics to arrive at a definitive diagnosis. Here, we examine the main uses of this strategy and analyse its benefits and drawbacks [6]. The uses of molecular methods for soft and bone tumours will be the main emphasis of this review. Molecular methods are frequently used in pathology to study nucleic acids, such as RNA and DNA, using hybridization on a cut slide or polymerase chain reaction methods on isolated DNA or RNA for example, reverse transcriptase PCR, quantitative PCR [7]. A pathologist is essential to correctly leading these analyses. In particular: Only one suitable material should be chosen, with an acceptable quantity of important lesional tissue A diverse collection of tumours, primary soft tissue and bone lesions include benign and malignant lesions [8].

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。